| Literature DB >> 33708884 |
Zhi Lin1, Ying Huang1, Hua Jiang1, Di Zhang1, Yanwei Yang1, Xingchao Geng1, Bo Li1.
Abstract
BACKGROUND: The monkey is a primary species used in toxicological research. However, the failures of preclinical studies to predict a life-threatening "cytokine storm", which, for instance, rapidly occurred in six healthy volunteers with the CD28 superagonist monoclonal antibody (mAb) TGN1412 in the first-in-human phase I clinical trial, have emphasized a need to clarify the differences between human and monkey immune systems.Entities:
Keywords: Non-human primates (NHPs); immunotoxicity; lipopolysaccharide (LPS); phytohemagglutinin (PHA); toxicogenomics
Year: 2021 PMID: 33708884 PMCID: PMC7940909 DOI: 10.21037/atm-20-4548
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Primer sequences for real-time PCR
| Target gene | Forward Primer (5'---3') | Reverse Primer (3'---5') |
|---|---|---|
| Human | ACATACTCCAAACCTTTCCACC | TCAAAAACTTCTCCACAACCC |
| Human | TTGAAGCACCAAACCAGGA | AGAAGGCATCTTTACTACACAGC |
| Human | TCAGAGCAGCGATGGAGAAAT | CCCGACACAGGTAAGGGTAAA |
| Human | AATGACGAGTTCTTTACTTCTGGC | TGAGGACTGTGAGGGGCTTC |
| Human | CAGGGGGGACCTAGAGCAA | ATGAATGACAGCGAAACCAGTT |
| Human | TCAATGCCCCAGTCACCT | CCACAATGGTCTTGAAGATCA |
| Human | GCTGACCCCCTGAAGGTGTA | CAAGGAGTGCCTGCTCATTTC |
| Human | AAGAAGACAGTTCCTCCATTGA | GCTTGGATGTTTTAGAGGTTTC |
| Human | AGCCCGGTGTCATCTTCCT | CACACGCATGTTCCCAAGG |
| Monkey | CAAGAGCCAGGAACAAACCA | GCAAAACTGCACCTTCACACA |
| Monkey | TCGATAAAGAGGAGGAAGCTG | ACCGTTGAAGAGAGTGGAGTG |
| Monkey | CATTGGTTGTGAGTTTTGTGG | GTCTGGTAGGCAGGTCTTGG |
| Monkey | AGGAAGAAGACCCTGTGCG | GCAAGAAGTCTCAAAAGGTGGT |
| Monkey | GACCCTAAAGAATGGCCGA | GGGATTTCCAAGTTTCATAACC |
| Monkey | TGGTGATTCTTCTATAGCTCGCC | GGTGATTCTTCTATAGCTCGCC |
| Monkey | CACATCCTGCCCCTCAAAA | AACCCCTGGCTCACCTCTT |
| Monkey | AATGACACCCTCAATCAAACTA | TCATCTTGGGCACTCACATA |
| Monkey | ACTGCTGCCCTTGCTGTCCT | TGGCTGTTGGTCTCAAAGTAGTCA |
Figure 1Lymphocyte proliferation in response to PHA or LPS. Proliferation by human and cynomolgus PBMCs were measured via CCK-8 assay. An F-test of two regression line equations was used to compare trends for proliferation rates between human and monkey cells. Lines in red and blue indicate trend curves for proliferation of the human and monkey PBMCs, respectively. (A) The trend for the proliferation of PBMC was significantly different between humans and cynomolgus monkeys after PHA stimulation (*, P<0.05). (B) No significant difference in trends for proliferation was noted between human and cynomolgus monkey cells after LPS stimulation. PHA, phytohemagglutinin; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cells; CCK-8, Cell Counting Kit-8.
Figure 2Cytokine profiles of human and monkey PBMCs treated with PHA or control (n=3). Data are presented as the mean ± SD. Statistically significant differences compared with values of the control group are highlighted by asterisks (*, P<0.05, **, P<0.01). PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin; SD standard deviation.
Figure 3Cytokine profiles of human and monkey PBMCs treated with LPS or control (n=3). Data are presented as the mean ± SD. Statistically significant differences compared with values of control group are highlighted by asterisks (*, P<0.05, **, P<0.01). PBMC, peripheral blood mononuclear cells; LPS, lipopolysaccharide; SD, standard deviation.
Cytokines induced by PHA and LPS in human and monkey
| Cytokines | PHA | LPS | |||
|---|---|---|---|---|---|
| Human | Monkey | Human | Monkey | ||
| IFN-γ | X | X | X | O | |
| TNF-α | X | X | O | O | |
| IL-2 | X | X | X | X | |
| IL-4 | X | O | O | O | |
| IL-5 | X | O | O | O | |
| IL-6 | X | O | X | X | |
| IL-8 | X | X | X | X | |
| IL-10 | X | X | X | X | |
| IL-12 | X | X | O | O | |
| IL-17 | X | X | O | O | |
| IL-23 | X | X | O | O | |
With PHA/LPS stimulation, statistically significant differences comparing with values of control group are present as “X”. No significant differences comparing with values of control group are present as “O”. Value significantly different from control group at P<0.05 or P<0.01.
Figure 4Up- and down-regulated genes in human and cynomolgus PBMCs treated with PHA (2 or 10 µg/mL) or LPS (2 or 10 µg/mL) compared to control. Bar charts in gray and dark represent the number of up- and downregulated genes, respectively. PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin; LPS, lipopolysaccharide.
Top-ten biological functions identified by significant enrichment GO analysis in monkey and human PBMCs after PHA stimulation
| GO term (biological process) | P value# | DEGs* (2 μg/mL PHA) | DEGs (10 μg/mL PHA) |
|---|---|---|---|
| Human | |||
| Immune responseф | −2.22×10–16 | 12 | 71 |
| Mitotic cell cycle | 3.33×10–16 | 11 | 70 |
| Cytokine-mediated signaling pathway | 3.33×10–16 | 2 | 43 |
| DNA strand elongation involved in DNA replication | 5.55×10–16 | 1 | 21 |
| Interferon-gamma-mediated signaling pathway | 2.00×10–15 | 0 | 26 |
| DNA replicationф | 3.79×10–14 | 4 | 37 |
| Cell division | 4.07×10–14 | 10 | 52 |
| Inflammatory response | 5.35×10–14 | 11 | 46 |
| Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 1.57×10–13 | 0 | 12 |
| M phase of mitotic cell cycle | 4.08×10–13 | 6 | 28 |
| △Phosphatidylinositol-mediated signaling | 4.74×10–5 | 6 | 14 |
| △Chemotaxisф | △1.53×10–6 | 7 | 25 |
| △Mitosis | △4.75×10–6 | 8 | 31 |
| △Negative regulation of caspase activity | △7.21×10–5 | 4 | 9 |
| Monkey | |||
| DNA-dependent DNA replication initiation | 3.30×10–8 | 0 | 4 |
| Immune responseф | 6.29×10–7 | 6 | 9 |
| DNA replicationф | 3.02×10–5 | 0 | 5 |
| Anti-apoptosis | 7.39×10–5 | 2 | 5 |
| Chromosome organization | 0.00016 | 0 | 3 |
| Regulation of cell shape | 0.00017 | 1 | 4 |
| Astrocyte cell migration | 0.00019 | 1 | 2 |
| Positive regulation of cholesterol efflux | 0.00032 | 1 | 2 |
| Chemotaxisф | 0.00070 | 1 | 3 |
| Apoptotic cell clearance | 0.00087 | 1 | 2 |
| △Antigen processing and presentation of peptide antigen via MHC class I | △3.47×10–13 | 5 | 1 |
| △Antigen processing and presentation | △4.07×10–10 | 5 | 1 |
*, DEGs: number of differently expression genes identified by microarray in 2 or 10 μg/mL PHA groups; #, P value for enrichment; △, that means these top-ten GO terms are identified in 2 μg/mL PHA group; ф, the same GO terms used in both human and monkey groups.
Figure 5Venn diagrams of DEGs in human and monkey PBMCs after PHA or LPS stimulation (10 µg/mL). The number of genes that showed expression changes at a two-fold level are shown. DEGs, differentially expressed genes; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; LPS, lipopolysaccharide.
Top-ten 10 DE genes in human PBMCs after PHA stimulation
| Gene symbol | Gene name | FC | Q-value |
|---|---|---|---|
| Up-regulation | |||
| | Cyclin B2 | 16.9 | 0 |
| | DNA topoisomerase II alpha | 16.6 | 0 |
| | Thymidylate synthetase | 13.6 | 0 |
| | Centrosomal protein 55 | 13.5 | 0 |
| | PCNA Clamp Associated Factor | 12.8 | 0 |
| | Kinesin family member 14 | 12.2 | 0 |
| | Centromere protein F | 11.6 | 0 |
| | Kinesin family member 23 | 11.3 | 0 |
| | Hyaluronan-mediated motility receptor | 11.3 | 0 |
| | Stromal antigen 3 | 10.9 | 0 |
| Down-regulation | |||
| CCL13 | C-C motif chemokine ligand 13 | 0.01 | 2.840 |
| CLC | Charcot-Leyden crystal galectin | 0.02 | 2.840 |
| FCER1A | Fc fragment of IgE receptor Ia | 0.02 | 2.840 |
| MS4A6A | Membrane spanning 4-domains A 6A | 0.03 | 2.840 |
| CPVL | Carboxypeptidase vitellogenic-like | 0.03 | 2.840 |
| FUCA1 | Alpha-L-fucosidase 1 | 0.03 | 2.840 |
| STAB1 | Stabilin 1 | 0.04 | 2.840 |
| ALDH1A1 | Aldehyde dehydrogenase 1 family member A1" | 0.05 | 2.840 |
| GPNMB | Glycoprotein nmb | 0.05 | 2.840 |
FC, fold change.
Top-ten 10 DE genes in monkey PBMCs after PHA stimulation
| Gene symbol | Gene name | FC | Q-value |
|---|---|---|---|
| Up-regulation | |||
| | Regulator of G-protein signaling 8 | 5.8 | 0 |
| | Chemokine (C motif) ligand 1 | 4.9 | 0 |
| | DNA topoisomerase II alpha | 4.7 | 1.962 |
| | Cell division cycle 20 | 4.2 | 0 |
| | Centromere protein W | 4.1 | 0 |
| | Minichromosome maintenance complex component 4 | 3.5 | 0 |
| | PTTG1 regulator of sister chromatid separation, securin | 3.4 | 0 |
| | Centromere protein M | 3.3 | 0 |
| | Cytochrome c oxidase assembly factor 1 homology | 3.1 | 0 |
| | regulator of G protein signaling 1 | 3.1 | 0 |
| Down-regulation | |||
| | Membrane spanning 4-domains A4A | 0.1 | 0 |
| | Complement C1q A chain | 0.1 | 0 |
| | C-C motif chemokine ligand 2 | 0.2 | 0 |
| | Heme oxygenase 1 | 0.2 | 0 |
| | Cathepsin L | 0.2 | 0 |
| | Solute carrier family 40 member 1 | 0.3 | 0 |
| | Cathepsin L-1 pseudogene | 0.3 | 0 |
| | Selenoprotein P | 0.3 | 0 |
| | Solute carrier organic anion transporter family member 2B1 | 0.3 | 0 |
FC, fold change.
Overlap DE genes in human and monkey PBMCs after PHA stimulation
| GO term (P value) | Overlap DEGs (FC: h/m) | UniqH DEGs | UniqM DEGs |
|---|---|---|---|
| Immune response: |
|
| |
| Inflammatory response: |
|
| |
| Chemotaxis: |
|
| |
| DNA replication: |
| ||
| DNA–dependent DNA replication initiation: |
| ||
| Cell division: |
| ||
| Mitosis: |
|
FC, fold change; Ph, P value of human; Pm, P value of monkey; h/m, human/monkey.
Top-ten biological functions identified by significant enrichment GO analysis in monkey and human PBMCs after LPS stimulation
| GO term (biological process) | P value# | DEGs* (2 μg/mL LPS) | DEGs (10 μg/mL LPS) |
|---|---|---|---|
| Human | |||
| Antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIф | 0 | 11 | 13 |
| Interferon-gamma-mediated signaling pathway | 1.11×10–16 | 14 | 23 |
| Immune responseф | 3.33×10–16 | 32 | 53 |
| Cytokine-mediated signaling pathway | 1.11×10–16 | 19 | 33 |
| Chemotaxis | 1.11×10–11 | 13 | 21 |
| T cell co-stimulation | 5.18×10–11 | 11 | 16 |
| Inflammatory response | 1.58×10–10 | 17 | 2 |
| T cell receptor signaling pathway | 2.89×10–9 | 11 | 15 |
| Innate immune response | 9.11×10–8 | 13 | 23 |
| Platelet degranulation | 3.13×10–7 | 6 | 13 |
| △Phagocytosis, recognition | △2.60×10–6 | 3 | 3 |
| △Positive regulation vascular endothelial growth factor production | △1.08×10–5 | 4 | 5 |
| Monkey | |||
| Antigen processing and presentation of peptide antigen via MHC Class I | −2.22×10–16 | 13 | 13 |
| Antigen processing and presentation | 0 | 22 | 23 |
| Immune responseф | 8.88×10–16 | 30 | 33 |
| Antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIф | 2.83×10–9 | 6 | 6 |
| Chaperone-mediated protein folding requiring cofactor | 0.00015 | 3 | 3 |
| Sarcomere organization | 0.00028 | 3 | 3 |
| Positive chemotaxis | 0.00061 | 2 | 3 |
| Cellular iron ion homeostasis | 0.00092 | 0 | 3 |
| Aerobic respiration | 0.00148 | 1 | 2 |
| Antigen processing and presentation of exogenous peptide antigen via MHC Class II | 0.00148 | 2 | 2 |
| △Electron transport chain | △0.00017 | 4 | 3 |
| △Translation | △0.00125 | 9 | 8 |
| △ATP synthesis coupled electron transport | △0.00150 | 2 | 2 |
*, DEGs: number of differently expression genes identified by microarray in 2 or 10 μg/mL LPS groups; #, P value for enrichment; △, that means these top-ten GO terms are identified in 2 μg/mL LPS group; ф, the same GO terms used in both human and monkey groups.
Top-ten 10 DE genes in human PBMCs after LPS stimulation
| Gene symbol | Gene name | FC | Q-value |
|---|---|---|---|
| Up-regulation | |||
| | Metallothionein 1H | 28.6 | 0 |
| | C-X-C motif chemokine ligand 1 | 24.2 | 0 |
| | Metallothionein 1G | 19.3 | 0 |
| | C-X-C motif chemokine ligand 1 | 16.8 | 0 |
| | Interleukin 1 beta | 15.6 | 0 |
| | Interleukin 8 | 6.4 | 0 |
| | C-X-C motif chemokine ligand 5 | 14.0 | 0 |
| | C-X-C motif chemokine ligand 2 | 8.1 | 0 |
| | Resistin | 7.8 | 11.047 |
| | Metallothionein 1M | 7.6 | 0 |
| Down-regulation | |||
| | Lactotransferrin | 0.04 | 100 |
| | Aldehyde dehydrogenase 1 family member A1 | 0.05 | 100 |
| | Membrane spanning 4-domains A6A | 0.05 | 100 |
| | Complement C1q A chain | 0.05 | 100 |
| | Interferon alpha inducible protein 27 | 0.07 | 100 |
| | C-X-C motif chemokine ligand 9 | 0.09 | 100 |
| | Apolipoprotein B mRNA editing enzyme catalytic subunit 3B | 0.09 | 100 |
| | Apolipoprotein C1 | 0.1 | 100 |
| | Complement C1q C chain | 0.1 | 100 |
FC, fold change.
Top-ten 10 DE genes in monkey PBMCs after LPS stimulation
| Gene symbol | Gene name | FC | Q-value |
|---|---|---|---|
| Up-regulation | |||
| | Major histocompatibility complex, class I, A | 11.3 | 0 |
| | Major histocompatibility complex, class I, B | 11.3 | 0 |
| | Major histocompatibility complex, class I, A | 11.3 | 0 |
| | Major histocompatibility complex, class I, B | 10.7 | 0 |
| | Major histocompatibility complex, class I, I | 10.2 | 0 |
| | Major histocompatibility complex, class I, E | 10.2 | 0 |
| | HLA class I histocompatibility antigen, B-67 alpha chain-like | 9.6 | 0 |
| | Major histocompatibility complex, class I, E | 9.2 | 0 |
| | Major histocompatibility complex, class I, F | 8.4 | 0 |
| | actin beta | 7.7 | 19.539 |
There were 562 DEG in 10 μg/mL LPS groups after LPS stimulation, but only 30 of them were down regulate with Q-value (%) of 103.376 and FC of 0.269 to 0.499. Because of the lack of significance, they were not listed in the table. FC, fold change.
Overlap DE genes in human and monkey PBMCs after LPS stimulation
| GO term (P value) | Overlap DEGs (FC: h/m) | UniqH DEGs | UniqM DEGs |
|---|---|---|---|
| Immune response: (Ph =3.33×10–16); (Pm =8.88×10–7) |
|
| |
| Cytokine–mediated signaling pathway: (Ph =1.11×10–11); (Pm =0.003845) |
|
| |
| Chemotaxis: (Ph =1.11×10–11); (Pm =0.00647) |
|
| |
| Inflammatory response: (Ph =1.58×10–10); (Pm =0.002622) |
|
|
FC, fold change; Ph, P value of human; Pm, P value of monkey; h/m, human/monkey.
Figure 6Effects of PHA and LPS on select gene expression in PBMCs. Impact of 10 µg/mL of PHA on the expression of PLK1, PCNA, MCM6, IL8, CDKN2C, and CCL2, and that of 10 µg/mL of LPS on IL-8, IL-1A, CD74, and CCL3, were validated by qRT-PCR. Fold-changes in expression levels between the PHA group and control are indicated in A (monkey) and B (human). Fold-changes in the expression levels between the LPS and control groups are indicated in C (monkey) and D (human). The qRT-PCR data are presented as means ± SD of three independent samples. Array data were calculated using SAM software. PHA, phytohemagglutinin; LPS, lipopolysaccharide; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SD, standard deviation; SAM, significance analysis of microarray.